Put companies on watchlist
Marinomed Biotech AG
ISIN: ATMARINOMED6
WKN: A2N9MM
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Marinomed Biotech AG · ISIN: ATMARINOMED6 · EQS - adhoc news (81 News)
Country: Austria · Primary market: Austria · EQS NID: 1979933
02 September 2024 05:46PM

Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights


EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action
Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights

02-Sep-2024 / 17:46 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Korneuburg, Austria, 02. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board decided today to evaluate a capital increase of up to 154,053 new shares to be issued from the Authorized Capital 2024, subject to the direct exclusion of statutory subscription rights of existing shareholders, to finance the ongoing costs in the restructuring proceedings, to finance part of the restructuring plan proposal and for costs of continuing operations. This corresponds to up to 10% of the Company's existing share capital.

For the purpose of the evaluation, the Management Board will enter into discussions with selected investors regarding the potential transaction and the transaction documentation. The actual implementation of the capital increase depends on the outcome of these discussions and is subject to further resolution by the Management Board and approval of the Supervisory Board. In addition, the restructuring proceedings require the approval of the restructuring administrator. These approvals have not yet been obtained.

If the capital increase is implemented, the Management Board is considering a possible second capital increase of 10% of the Company's existing share capital, with exclusion of the statutory subscription rights of existing shareholders.

+++ End of ad-hoc announcement +++ 
 


End of Inside Information

02-Sep-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com


Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market)
EQS News ID: 1979933

 
End of Announcement EQS News Service

1979933  02-Sep-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1979933&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Marinomed Biotech AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.